Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 188   

Articles published

PFE 28.89 -0.05 (-0.17%)
price chart
3 Reasons Pfizer Inc.'s Stock Could Rise
Pfizer (NYSE: PFE ) , arguably the preeminent pharmaceutical company in the world, continues to pump out billions in free cash flow annually, deliver delectable gross margins, and pay out an annual dividend that puts the S&P 500 average yield of 2% to ...
Related articles »  
Pfizer Files NDA For Breast Cancer Drug
Pfizer Inc. (PFE) reported today that its new drug application (NDA) for Palbociclib to the Food and Drug Administration (FDA) is complete.
Pfizer Submits Palbociclib Marketing Application to the FDA - Analyst Blog  NASDAQ
Pfizer Announces Submission of Palbociclib New Drug Application to the FDA  MarketWatch
Related articles »  
5 Things Pfizer Inc.'s Management Wants You to Know
For the quarter, Pfizer reported that revenue slipped 2%, or $200 million, to $12.77 billion. Profits were also a mixed tale with Pfizer's adjusted income dipping 6% and its adjusted EPS rising 4%. The company also lowered its full-year revenue ...
Pfizer Inc. (PFE): Trouble Ahead For The Stock  ETF Daily News
Intel Corporation (NASDAQ:INTC), Pfizer Inc. (NYSE:PFE), Microsoft ...  US Trade Media
Related articles »  
Pfizer: Continuing The Search For Tax Inversion
The next big pharmaceutical company that might be making a move to relocate out of the US for tax benefits could be Pfizer Inc. (PFE). The idea behind tax inversion deals is to acquire companies in countries where the tax rate is lower than the US. In ...
Investors sent on a wild ride by hostile deals  MarketWatch
Related articles »  
Pfizer's Prevnar 13 Gets ACIP Approval For Elderly
Yesterday, Pfizer Inc. (PFE) announced it had won the approval of an influential US advisory panel, for its drug Prevnar 13.
US Panel Says Seniors Should Get Pfizer's Prevnar 13  Bloomberg
Advisory Committee on Immunization Practices Votes to Recommend Pfizer's ...  MarketWatch
Related articles »  
Pfizer Inc. (PFE) Tops DJIA Gainers for August 14
The Dow closed at 16,713.60 on Thursday, which is a 0.37% move from yesterday's close. Pfizer Inc. led all gainers with a 1.84% jump.
Pfizer Megadeal Still in Sight After Astra: Real M&A
After being rejected by AstraZeneca Plc (AZN), Pfizer Inc. (PFE) still has a chance to clinch the drug industry's biggest deal.
Related articles »  
23andMe Announces Agreement with Pfizer Inc. to Research Genetics of ...
12, 2014 /PRNewswire/ -- 23andMe, the leading personal genetics company today announced an agreement with Pfizer Inc. in which the companies will aim to enroll 10,000 people with Inflammatory Bowel Disease (IBD) in a research initiative designed to ...
Pfizer, 23andMe Team up to Study Bowel Disease  ABC News
Pfizer to help 23andMe unravel genetic ties to bowel disease  Yahoo News
Related articles »  
Pfizer Faces Surge In Lawsuits Over Cholesterol Drug Lipitor
Pfizer Inc. (PFE) is facing an increasing number of lawsuits related to its anti-cholesterol drug Lipitor from women who accuse the company of deliberately withholding information about side effects pertaining to use of the drug.
How Will Pfizer (PFE) Stock React As Lawsuits Over Lipitor Grow?  TheStreet.com
Pfizer Inc. (NYSE:PFE) Facing Sharp Sword Of Surging Lipitor-Related ...  WallStreetPR
Related articles »  
Why Pfizer (PFE) Stock Is Up Today
NEW YORK (TheStreet) -- Shares of Pfizer Inc. (PFE_) are up 0.11% to $28.24 after the company won the backing of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, a key U.S.
Pfizer Price Target Cut to $34.00 (PFE)  WKRB News
Pfizer Sees Significant Growth in Short Interest (PFE)  Watch List News (press release)
Related articles »